Adjuvant BRAF plus MEK inhibition is more effective at delaying tumor recurrence in resected stage III CM than surgical management alone, and a clinical trial is underway to minimize side effects associated with this therapy (Atkinson et al., 2021; Dummer et al., 2020). This evidence concerns the gene MAP2K7 and neoplasm.